Rituximab Therapy for Severe Refractory Chronic Henoch-Schönlein Purpura

Academic Article

Abstract

  • To report on the efficacy of rituximab (RTX) therapy in standard treatment-refractory, chronic Henoch-Schönlein purpura, a retrospective chart review of 3 pediatric patients treated with RTX for severe refractory chronic Henoch-Schönlein purpura was performed. All 3 patients responded to 1 or 2 courses of RTX without serious adverse events. © 2009 Mosby, Inc. All rights reserved.

    • Authors

    Published In

    Digital Object Identifier (doi)

    Author List

  • Donnithorne KJ; Atkinson TP; Hinze CH; Nogueira JB; Saeed SA; Askenazi DJ; Beukelman T; Cron RQ

    • Start Page

  • 136

    • End Page

  • 139

    • Volume

  • 155

    • Issue

  • 1